经导管三尖瓣介入治疗经瓣膜右心室导联患者的处理。欧洲心律协会(EHRA)和ESC的欧洲经皮心血管干预协会(EAPCI)的科学声明,由心律学会(HRS)、亚太心律学会(APHRS)和加拿大心律学会(CHRS)批准。

IF 7.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Europace Pub Date : 2025-05-07 DOI:10.1093/europace/euaf061
Jean-Claude Deharo, Julien Dreyfus, Maria-Grazia Bongiorni, Haran Burri, Pascal Defaye, Michael Glikson, Nigel Lever, Antonio Mangieri, Blandine Mondésert, Jens Cosedis Nielsen, Maully Shah, Christoph Thomas Starck, Archana Rao, Christophe Leclercq, Fabien Praz, Sergio Richter, Nicolas Amabile, Alexander Breitenstein, Óscar Cano, Karol Čurila, Jamie Manlucu, Robert D Schaller, Hung-Fat Tse, Christian Veltmann, Zachary Whinnett
{"title":"经导管三尖瓣介入治疗经瓣膜右心室导联患者的处理。欧洲心律协会(EHRA)和ESC的欧洲经皮心血管干预协会(EAPCI)的科学声明,由心律学会(HRS)、亚太心律学会(APHRS)和加拿大心律学会(CHRS)批准。","authors":"Jean-Claude Deharo, Julien Dreyfus, Maria-Grazia Bongiorni, Haran Burri, Pascal Defaye, Michael Glikson, Nigel Lever, Antonio Mangieri, Blandine Mondésert, Jens Cosedis Nielsen, Maully Shah, Christoph Thomas Starck, Archana Rao, Christophe Leclercq, Fabien Praz, Sergio Richter, Nicolas Amabile, Alexander Breitenstein, Óscar Cano, Karol Čurila, Jamie Manlucu, Robert D Schaller, Hung-Fat Tse, Christian Veltmann, Zachary Whinnett","doi":"10.1093/europace/euaf061","DOIUrl":null,"url":null,"abstract":"<p><p>Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI.</p>","PeriodicalId":11981,"journal":{"name":"Europace","volume":" ","pages":""},"PeriodicalIF":7.9000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077151/pdf/","citationCount":"0","resultStr":"{\"title\":\"Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society.\",\"authors\":\"Jean-Claude Deharo, Julien Dreyfus, Maria-Grazia Bongiorni, Haran Burri, Pascal Defaye, Michael Glikson, Nigel Lever, Antonio Mangieri, Blandine Mondésert, Jens Cosedis Nielsen, Maully Shah, Christoph Thomas Starck, Archana Rao, Christophe Leclercq, Fabien Praz, Sergio Richter, Nicolas Amabile, Alexander Breitenstein, Óscar Cano, Karol Čurila, Jamie Manlucu, Robert D Schaller, Hung-Fat Tse, Christian Veltmann, Zachary Whinnett\",\"doi\":\"10.1093/europace/euaf061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI.</p>\",\"PeriodicalId\":11981,\"journal\":{\"name\":\"Europace\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.9000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077151/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Europace\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/europace/euaf061\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Europace","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/europace/euaf061","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

在接受经导管三尖瓣介入治疗(TTVI)的患者中,多达三分之一的患者使用了经瓣膜起搏器(PPM)或植入式心律转复除颤器(ICD)。由于导联和TTVI材料之间的潜在相互作用,包括导致导联入狱或损伤的风险,电生理学和介入心脏病学界都已注意到在这种情况下决策的复杂性。该文件由欧洲心律协会(EHRA)和ESC的欧洲经皮心血管干预协会(EAPCI)委托编写,审查了科学证据,为心脏小组讨论计划或已接受TTVI的PPM或ICD患者的管理提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society.

Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Europace
Europace 医学-心血管系统
CiteScore
10.30
自引率
8.20%
发文量
851
审稿时长
3-6 weeks
期刊介绍: EP - Europace - European Journal of Pacing, Arrhythmias and Cardiac Electrophysiology of the European Heart Rhythm Association of the European Society of Cardiology. The journal aims to provide an avenue of communication of top quality European and international original scientific work and reviews in the fields of Arrhythmias, Pacing and Cellular Electrophysiology. The Journal offers the reader a collection of contemporary original peer-reviewed papers, invited papers and editorial comments together with book reviews and correspondence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信